Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
Clinical trial NCT03319940 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03319940
- Sponsor
- Amgen
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-12-26
- Primary completion
- 2026-12-31
- Enrollment
- 269
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.